Search Result

Results for "

Monoamine Oxidase

" in MCE Product Catalog:

By Targets:	Monoamine Oxidase (107) 5-HT Receptor (1) Adenosine Receptor (2) Adrenergic Receptor (5) AMPK (1) Amyloid-β (2) Antibiotic (2) Apoptosis (3) Autophagy (1) Bacterial (3) Cholinesterase (ChE) (7) COMT (2) Cytochrome P450 (1) Dopamine Transporter (1) Dopamine β-hydroxylase (1) Endogenous Metabolite (2) Estrogen Receptor/ERR (1) Guanylate Cyclase (3) HDAC (1) Histamine Receptor (1) Histone Demethylase (8) HSV (1) iGluR (1) Imidazoline Receptor (3) Microtubule/Tubulin (2) NO Synthase (3) Parasite (3) Phosphatase (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (9) Endocrinology (4) Infection (10) Inflammation/Immunology (8) Metabolic Disease (3) Neurological Disease (82)

By Targets:

Monoamine Oxidase (107)

5-HT Receptor (1)

Adenosine Receptor (2)

Adrenergic Receptor (5)

AMPK (1)

Amyloid-β (2)

Antibiotic (2)

Apoptosis (3)

Autophagy (1)

Bacterial (3)

Cholinesterase (ChE) (7)

COMT (2)

Cytochrome P450 (1)

Dopamine Transporter (1)

Dopamine β-hydroxylase (1)

Endogenous Metabolite (2)

Estrogen Receptor/ERR (1)

Guanylate Cyclase (3)

HDAC (1)

Histamine Receptor (1)

Histone Demethylase (8)

HSV (1)

iGluR (1)

Imidazoline Receptor (3)

Microtubule/Tubulin (2)

NO Synthase (3)

Parasite (3)

Phosphatase (1)

By Research Areas:

Cancer (19)

Cardiovascular Disease (9)

Endocrinology (4)

Infection (10)

Inflammation/Immunology (8)

Metabolic Disease (3)

Neurological Disease (82)

110

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Monoamine Oxidase Monoamine Transporter Xanthine Oxidase NADPH Oxidase

Cat. No.	Product Name	Target	Research Areas

HY-E70074

**Monoamine oxidase**	Monoamine Oxidase	Neurological Disease
Monoamine oxidase is an enzyme composed of different polypeptides. Monoamine oxidation catalyzes the oxidative deamination of various biological amines in brain and peripheral tissues by producing hydrogen peroxide. Monoamine oxidase plays an important role in maintaining the regulation of synaptic transmission, emotional behavior and other brain functions.

HY-144824

Monoamine oxidase/Aromatase-IN-1	Cytochrome P450 Monoamine Oxidase	Cancer Neurological Disease
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and aromatase dual inhibitor with IC₅₀s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer.

HY-143245

Monoamine Oxidase B inhibitor 2	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.33 nM. Monoamine Oxidase B inhibitor 2 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 2 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study.

HY-143244

Monoamine Oxidase B inhibitor 1	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study.

HY-W224327

Pheniprazine β-Phenylisopropylhydrazine	Monoamine Oxidase	Neurological Disease
Pheniprazine is a potent and long acting inhibitor of **monoamine oxidase**. Pheniprazine has the potential for the research of depression.

HY-W193398

N-2-Cyclohexylethyl-N-methylamine	Monoamine Oxidase	Cardiovascular Disease
N-2-Cyclohexylethyl-N-methylamine is an amine from A.ridigula Benth for a reduction of **monoamine oxidase (MAO**) activity.

HY-W015490

1,4-Naphthoquinone	Monoamine Oxidase	Cancer
1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity.

HY-148159

Safrazine	Monoamine Oxidase	Neurological Disease
Safrazine is an irreversible, non-specific and orally active monoamine oxidase (MAO) inhibitor. Safrazine can be used for the research of depression.

HY-151210

MAO-B-IN-17	Monoamine Oxidase	Neurological Disease
MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC₅₀ value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research.

HY-N9329

Glicoricone	Monoamine Oxidase Estrogen Receptor/ERR	Metabolic Disease
Glicoricone, a phenolic compound, is isolated from a species of licorice. Glicoricone is an inhibitor of monoamine oxidase (MAO), with an IC₅₀ of 140 μM. Glicoricone binds to estrogen receptor (ER) and shows estrogen antagonist activity.

HY-N9540

Methyl citrate	Monoamine Oxidase	Neurological Disease
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino.

HY-135265

Moclobemide N-Oxide Ro 12-5637	Monoamine Oxidase	Neurological Disease
Moclobemide N-Oxide (Ro 12-5637) is N-oxide metabolite of Moclobemide. Moclobemide N-Oxide retains certain MAO-A (monoamine oxidase) inhibitory activity, but is generally present in low concentrations. Moclobemide N-Oxide can be detected by UV absorption at 240 nm.

HY-19915B

Contezolid acefosamil sodium MRX-4 sodium	Bacterial Antibiotic Monoamine Oxidase	Infection Inflammation/Immunology
Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid acefosamil sodium (MRX-4) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI).

HY-17447G

Tranylcypromine SKF 385	Monoamine Oxidase	Endocrinology Cardiovascular Disease
Tranylcypromine (SKF 385) (GMP) is Tranylcypromine (HY-17447) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tranylcypromine (SKF 385) is a potent monoamine oxidase (MAO) inhibitor.

HY-151208

MAO-B-IN-16	Monoamine Oxidase	Neurological Disease
MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC₅₀ of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease.

HY-B1558A

Bifemelane hydrochloride MCI-2016	Monoamine Oxidase	Neurological Disease
Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a K_i of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a K_i of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.

HY-B0534

Moclobemide Ro111163	Monoamine Oxidase	Neurological Disease
Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC₅₀ of 6.061 μM for hMAO-A.Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-10399

Ladostigil TV-3326	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease.

HY-10399A

Ladostigil hydrochloride TV-3326 hydrochloride	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease.

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective MAO-B (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM.

HY-120419

PF9601N	Monoamine Oxidase	Neurological Disease
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity.

HY-19333

OG-L002	Histone Demethylase Monoamine Oxidase HSV	Infection
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC₅₀ of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC₅₀s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.

HY-14202

Lazabemide hydrochloride Ro 19-6327 hydrochloride	Monoamine Oxidase	Neurological Disease
Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease.

HY-14201

Lazabemide Ro 19-6327	Monoamine Oxidase	Neurological Disease
Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease.

HY-103164

(E)-8-(3-Chlorostyryl)caffeine	Adenosine Receptor Monoamine Oxidase	Neurological Disease
(E)-8-(3-Chlorostyryl)caffeine is a selective adenosine A_2A receptor antagonist. (E)-8-(3-Chlorostyryl)caffeine inhibits monoamine oxidase B (MAO-B) with a K_i value of 70 nM by a pathway that is independent of its actions on the A_2A receptor. (E)-8-(3-Chlorostyryl)caffeine has the potential for Parkinson's disease research.

HY-W008566

Norharmane Norharman; β-Carboline	Monoamine Oxidase Endogenous Metabolite	Cancer Infection Neurological Disease
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible **monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for MAO-A and MAO-B*, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana* seedlings.

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of MAO-B activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS.

HY-13929

Isocarboxazid	Monoamine Oxidase	Neurological Disease
Isocarboxazid is a non-selective and irreversible inhibitor of **monoamine oxidase, with an IC₅₀** of 4.8 μM for rat brain monoamine oxidase in vitro.

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease.

HY-146383

H3R antagonist 2	Histamine Receptor Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
H3R antagonist 2 (Compound 23) is a multitarget histamine H₃ receptor (H₃R) antagonist with a K_i of 170 nM for hH₃R . H3R antagonist 2 shows inhibitory effects with IC₅₀ values of 180, 880 and 775 nM for acetylcholinesterase, butyrylcholinesterase and *human monoamine* oxidase B (hMAO B)**, respectively. H3R antagonist 2 shows favorable anti-neuropathic pain and memory-enhancing effects. H3R can across BBB.

HY-13779

J-147	Monoamine Oxidase Dopamine Transporter	Neurological Disease
J-147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J-147 can readily pass the blood brain barrier (BBB). J-147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter with EC₅₀ values of 1.88 μM and 0.649 μM, respectively. J-147 has potential for the treatment of Alzheimer’s disease (AD).

HY-139647

(+)-Cinchonaminone
Monoamine Oxidase Others

(+)-Cinchonaminone shows monoamine oxidase (MAO) inhibitory activity.
HY-B1413

Eprobemide
LIS 630
Monoamine Oxidase Neurological Disease

Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A.

(+)-Cinchonaminone	Monoamine Oxidase	Others
(+)-Cinchonaminone shows monoamine oxidase (MAO) inhibitory activity.

Eprobemide LIS 630	Monoamine Oxidase	Neurological Disease
Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A.

HY-146314

MAO-B-IN-9	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects.

HY-101392

Harmane	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Cancer Neurological Disease
Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively). Harmane exhibits comutagenic effect.

HY-22385A

Salsolidine hydrochloride	Monoamine Oxidase	Neurological Disease
Salsolidine hydrochloride, a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive *MAO A (monoamine* oxidase A)** inhibitor.

HY-17447

Tranylcypromine
SKF 385
Monoamine Oxidase Endocrinology Cardiovascular Disease

Tranylcypromine (SKF 385) is a potent monoamine oxidase (MAO) inhibitor.
HY-U00015

MAO-IN-1
Monoamine Oxidase Neurological Disease

MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

Tranylcypromine SKF 385	Monoamine Oxidase	Endocrinology Cardiovascular Disease
Tranylcypromine (SKF 385) is a potent monoamine oxidase (MAO) inhibitor.

MAO-IN-1	Monoamine Oxidase	Neurological Disease
MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

HY-B1199

Nialamide	Monoamine Oxidase	Neurological Disease
Nialamide is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.

HY-100178

CX-157
Monoamine Oxidase Neurological Disease

CX-157 is a reversible inhibitor of monoamine oxidase-A (MAO-A) with an EC₅₀ of 19.3 ng/mL.
HY-13339

Brofaromine
CGP 11305A
Monoamine Oxidase Neurological Disease

Brofaromine (CGP 11305A) is a monoamine oxidase (MAO) inhibitor with IC₅₀ of 0.2 μM for MAO-A.
HY-U00343

MAO-B-IN-1
Monoamine Oxidase Neurological Disease

MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

CX-157	Monoamine Oxidase	Neurological Disease
CX-157 is a reversible inhibitor of **monoamine oxidase-A (MAO-A) with an EC₅₀** of 19.3 ng/mL.

Brofaromine CGP 11305A	Monoamine Oxidase	Neurological Disease
Brofaromine (CGP 11305A) is a **monoamine oxidase (MAO) inhibitor with IC₅₀ of 0.2 μM for MAO-A**.

MAO-B-IN-1	Monoamine Oxidase	Neurological Disease
MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

HY-14197A

Clorgyline hydrochloride	Monoamine Oxidase	Metabolic Disease
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research; structurally related to Pargyline.

HY-119885A

(±)-Amiflamine
FLA 336
Monoamine Oxidase Neurological Disease

(±)-Amiflamine (FLA 336) is a potent monoamine oxidase-A (MAO-A) inhibitor with a pIC₅₀ of 5.57.
HY-148145

Mebanazine
Monoamine Oxidase Neurological Disease

Mebanazine is a potent monoamine oxidase (MAO) inhibitor. Mebanazine can be used in research of depression.
HY-148146

Phenoxypropazine
Monoamine Oxidase Neurological Disease

Phenoxypropazine is a potent monoamine oxidase (MAO) inhibitor. Phenoxypropazine can be used in research of depression.
HY-14196

Toloxatone
MD 69276
Monoamine Oxidase Neurological Disease

Toloxatone (MD 69276) is a reversible monoamine oxidase A (MAO_A) inhibitor. Antidepressant.

(±)-Amiflamine FLA 336	Monoamine Oxidase	Neurological Disease
(±)-Amiflamine (FLA 336) is a potent monoamine oxidase-A (MAO-A) inhibitor with a pIC₅₀ of 5.57.

Mebanazine	Monoamine Oxidase	Neurological Disease
Mebanazine is a potent monoamine oxidase (MAO) inhibitor. Mebanazine can be used in research of depression.

Phenoxypropazine	Monoamine Oxidase	Neurological Disease
Phenoxypropazine is a potent monoamine oxidase (MAO) inhibitor. Phenoxypropazine can be used in research of depression.

HY-B0886A

Iproniazid	Monoamine Oxidase	Neurological Disease
Iproniazid is a non-selective, irreversible monoamine oxidase (MAO) inhibitor of the hydrazine class. Iproniazid has antidepressive activity.

HY-Y0882

Hydroxyamine hydrochloride	Monoamine Oxidase	Cardiovascular Disease
Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis.

HY-B0886

Iproniazid phosphate	Monoamine Oxidase	Neurological Disease
Iproniazid phosphate is a non-selective, irreversible monoamine oxidase (MAO) inhibitor of the hydrazine class. Iproniazid phosphate has antidepressive activity.

HY-101578

2614W94	Monoamine Oxidase	Neurological Disease
2614W94 is a selective, reversible inhibitor of **monoamine oxidase-A with a competitive mechanism of inhibition and IC₅₀ of 5 nM and K_i** of 1.6 nM with serotonin as substrate.

HY-120017

Befloxatone MD-370503	Monoamine Oxidase	Neurological Disease
Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC₅₀=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential.

HY-111588

Xanthoangelol	Apoptosis Monoamine Oxidase Bacterial AMPK	Cancer Infection Inflammation/Immunology
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-148158

Pivalylbenzhydrazine Pivhydrazine	Monoamine Oxidase	Inflammation/Immunology Neurological Disease
Pivalylbenzhydrazine (Pivhydrazine) is a potent monoamine oxidase (MAO) inhibitor. Pivalylbenzhydrazine decreases cartilage growth in normal rats. Pivalylbenzhydrazine can be used in research of depression.

HY-B1111

Amitraz BTS-27419	Adrenergic Receptor Monoamine Oxidase Parasite	Infection Endocrinology
Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.

HY-142706

MAO A/HDAC-IN-1
Monoamine Oxidase HDAC Cancer

MAO A/HDAC-IN-1 is a dual inhibitor of monoamine oxidase A (MAO A) and HDAC. MAO A/HDAC-IN-1 can be used for glioma research.

HY-N7603

Rubrofusarin triglucoside	Monoamine Oxidase	Neurological Disease
Rubrofusarin triglucoside is a glycoside compound isolated from Cassia obtusifolia Linn seeds. Rubrofusarin triglucoside inhibits *human monoamine* oxidase A (hMAO-A) with an IC₅₀** of 85.5 μM.

HY-15386

Cimoxatone MD 780515	Monoamine Oxidase	Metabolic Disease
Cimoxatone (MD 780515) is a reversible, selectively and orally active *type A monoamine* oxidase (MAO-A)** inhibitor. Cimoxatone enhances the anorectic action of Serotonin (HY-B1473A).

HY-22385B

(S)-Salsolidine	Monoamine Oxidase Endogenous Metabolite	Neurological Disease
(S)-Salsolidine is a weak monoamine oxidase (MAO) inhibitor (K_i=63 μM). The R enantiomer of Salsolidine is more potent than the S form (K_i=26 μM).

HY-14605BS

Rasagiline-13C3 mesylate racemic AGN1135-¹³C₃; TVP1012-¹³C₃ racemic	Monoamine Oxidase	Neurological Disease
Rasagiline-¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1].

HY-147362

MAO-B-IN-14	Monoamine Oxidase	Neurological Disease
MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC₅₀ of 0.95 μM and a K_i of 0.55 μM against human MAO-B.

HY-A0091

Pargyline hydrochloride	Monoamine Oxidase	Cancer Cardiovascular Disease
Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities.

HY-141681

THK-5475	Monoamine Oxidase	Neurological Disease
THK-5475 is a precursor of THK-5470, a monoamine oxidase-B(MAO-B) imaging probe, could be used for neurological diseases study (from patent EP2019-846498).

HY-A0091A

Pargyline	Monoamine Oxidase	Cancer Cardiovascular Disease
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities.

HY-17447B

(1S,2R)-Tranylcypromine hydrochloride (1S,2R)-SKF 385 hydrochloride	Monoamine Oxidase Histone Demethylase	Neurological Disease
(1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1.

HY-Y0882S1

Hydroxylamine-d3 hydrochloride	Monoamine Oxidase	Cardiovascular Disease
Hydroxylamine-d₃ (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].

HY-146149

MAO-B-IN-11	Monoamine Oxidase	Neurological Disease
MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity.

HY-146150

MAO-B-IN-12	Monoamine Oxidase	Neurological Disease
MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity.

HY-B1111S1

Amitraz-d3 BTS-27419-d₃	Adrenergic Receptor Monoamine Oxidase Parasite	Infection Endocrinology
Amitraz-d₃ is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.

HY-14605

Rasagiline mesylate (R)-AGN1135 mesylate; TVP1012 mesylate	Monoamine Oxidase Autophagy Apoptosis	Neurological Disease
Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.

HY-14605A

Rasagiline (R)-AGN1135; TVP1012	Monoamine Oxidase	Neurological Disease
Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.

HY-N6057

Obtusin	Monoamine Oxidase	Neurological Disease
Obtusin, isolated from Cassia obtusifolia Linn seed, is a highly selective and competitive *human monoamine* oxidase-A (hMAO-A) inhibitor with an IC₅₀ of 11.12 μM and a K_i** of 6.15 μM. Obtusin plays a preventive role in neurodegenerative diseases, especially anxiety and depression.

HY-N8200

Cassiaside B2	Phosphatase Monoamine Oxidase 5-HT Receptor	Inflammation/Immunology
Cassiaside B2 is a protein tyrosine phosphatase 1B (PTP1B) and *human monoamine* oxidase A (hMAO-A) inhibitor. Cassiaside B2 possesses antiallergic and is a 5-HT2C** receptor agonist...

HY-19915

Contezolid MRX-I	Bacterial Antibiotic Monoamine Oxidase	Infection Inflammation/Immunology
Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI).

HY-W015490S

1,4-Naphthoquinone-d6	Monoamine Oxidase	Cancer
1,4-Naphthoquinone-d₆ is the deuterium labeled 1,4-Naphthoquinone[1]. 1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity[2].

HY-B0534S1

Moclobemide-d4 Ro111163-d₄	Monoamine Oxidase	Neurological Disease
Moclobemide-d₄ is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-100027A

Ro 41-1049 hydrochloride	Monoamine Oxidase	Neurological Disease
Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (MAO-A). An homogeneous population of high affinity binding sites for [³H]Ro 41-1049 is found in membrane preparations from human frontal cortex and placenta (K_d values of 16.5 and 64.4 nM, respectively).

HY-W083062

hMAO-B-IN-5	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-5(B15) is a potent, selective and reversible inhibitor of human monoamine oxidase hMAO-B with IC₅₀ of 0.12 μM. hMAO-B-IN-5 can pass through the blood-brain barrier and can be used in the research of neurodegenerative diseases.

HY-151094

FTEAA	Monoamine Oxidase	Neurological Disease
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both **monoamine oxidase with IC₅₀s of 0.52 μM (MAO-A), 1.02 μM (MAO-B**), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research.

HY-B1496

Tranylcypromine hemisulfate SKF 385 hemisulfate	Monoamine Oxidase Histone Demethylase	Neurological Disease
Tranylcypromine (SKF 385) hemisulfate is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hemisulfate is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Tranylcypromine has antidepressant effects.

HY-17447SA

Tranylcypromine-d5 hydrochloride SKF 385-d₅ (hydrochloride)	Monoamine Oxidase Histone Demethylase	Neurological Disease
Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

HY-N4037

Homopterocarpin (-)-Homopterocarpin; 3,9-Dimethoxypterocarpan	Monoamine Oxidase	Inflammation/Immunology
Homopterocarpin is an isoflavonoid that can be isolated from Pterocarpus erinaceus. Homopterocarpin has hepatoprotective and antioxidant properties. Homopterocarpin is a competitive reversible inhibitor of human monoamine *oxidase-B* with an IC₅₀ and a K_i of 0.72 and 0.21 μM for hMAO-B, respectively. Homopterocarpin can be used for the research of liver injury and oxidative stress.

HY-N7204

4-Hydroxyderricin	Monoamine Oxidase Dopamine β-hydroxylase	Neurological Disease
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective *MAO-B (Monoamine* oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits DBH (dopamine β-hydroxylase)** activity. 4-Hydroxyderricin has antidepressant activity.

HY-N2554

Osthenol Ostenol	Monoamine Oxidase	Neurological Disease
Osthenol (Ostenol), a prenylated coumarin isolated from the dried roots of Angelica pubescens, is selective, reversible, and competitive human monoamine oxidase-A (hMAO-A) inhibitor (K_i=0.26 µM). Osthenol potently inhibits recombinant hMAO-A with an IC₅₀ of 0.74 µM and shows a high selectivity index for hMAO-A versus hMAO-B.

HY-146312

AChE/BChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BChE/MAO-B-IN-1 (Compound 10) is a reversible and non-time-dependent AChE, BChE and MAO-B inhibitor with IC₅₀ values of 7.31, 0.56 and 26.1 μM for hAChE, hBChE and hMAO-B, respectively. AChE/BChE/MAO-B-IN-1 can cross the BBB and shows neuroprotective effects without cytotoxicity.

HY-10400

Ladostigil hemitartrate TV-3326 hemitartrate	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease.

HY-17447A

Tranylcypromine hydrochloride SKF 385 hydrochloride	Monoamine Oxidase	Neurological Disease
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression.

HY-Y0265

Isatin Indoline-2,3-dione	Monoamine Oxidase Apoptosis	Cancer Neurological Disease Cardiovascular Disease
Isatin (Indoline-2,3-dione) is a potent inhibitor of monoamine oxidase (MAO) with an IC₅₀ of 3 μM. Also binds to central benzodiazepine receptors (IC₅₀ against clonazepam, 123 μM). Also acts as an antagonist of both atrial natriuretic peptide stimulated and nitric oxide-stimulated guanylate cyclase activity. Shows effect on the serotonergic system.

HY-D0004

Azure B Azure B chloride	Monoamine Oxidase	Neurological Disease
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC₅₀s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects.

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research.

HY-B1359

Methylene blue trihydrate C.I. Basic Blue 9 trihydrate	Guanylate Cyclase Monoamine Oxidase NO Synthase Parasite	Cancer Infection Neurological Disease
Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures. Methylene blue trihydrate has antinociception, antimalarial, antidepressant and anxiolytic activity effects. Methylene Blue trihydrate has the potential for methemoglobinemias, neurodegenerative disorders and ifosfamide-induced encephalopathytreatment.

HY-141682

THK-5470	Monoamine Oxidase	Neurological Disease
THK-5470, a monoamine oxidase-B (MAO-B) imaging probe, could be used for neurological diseases study. THK-5470 shows remarkably high binding affinity against MAO-B with an IC50 value of 4.2 nM, low binding affinity against tau with an IC50 value of 4462 nM. THK-5470 has high selective binding property and high affinity (from patent EP2019-846498).

HY-152671

hMAO-B-IN-4	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC₅₀ value and a K_i value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC₅₀ value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research.

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride (1S,2R)-SKF 385-d₅ hydrochloride	Monoamine Oxidase	Neurological Disease
(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-14536

Methylene Blue Basic Blue 9; CI-52015; Methylthioninium chloride	Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin	Cancer Infection Neurological Disease
Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.

HY-D0958

Methylene blue hydrate Basic Blue 9 hydrate; CI-52015 hydrate; Methylthioninium chloride hydrate	Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin	Cancer Infection Inflammation/Immunology
Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.

HY-151388

hMAO-B/MB-COMT-IN-1	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).

HY-151390

hMAO-B/MB-COMT-IN-2	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-2 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).

HY-70057

Safinamide FCE 26743; EMD 1195686	Monoamine Oxidase	Neurological Disease
Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 µM) over MAO-A (IC₅₀=580 µM). Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 µM) than at resting (IC₅₀=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al.

HY-147908

Adenosine receptor inhibitor 2	Adenosine Receptor	Inflammation/Immunology
Adenosine receptor inhibitor 2 (compound 14b) is a potent AR (adenosine receptor) inhibitor. Adenosine receptor inhibitor 2 shows dual affinity toward A₁/A_2A ARs with higher affinity for the A₁- than the A_2AAR. Adenosine receptor inhibitor 2 has K_i values of 52.2 nM for the A₁AR and 167 nM for the A_2AAR.

HY-144673

LSD1-IN-12	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-12 (compound 2) is a potent LSD1 inhibitor, with K_i values of 1.1 μM (LSD1), 61 μM (LSD2), 2.3 μM (MAO-A), and 3.5 μM (MAO-B), respectively.

HY-70057A

Safinamide mesylate FCE 26743 mesylate; EMD 1195686 mesylate	Monoamine Oxidase	Neurological Disease Cardiovascular Disease
Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 µM) over MAO-A (IC₅₀=580 nM). Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 µM) than at resting (IC₅₀=262 µM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al.

HY-101392S1

Harmane-d2	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Cancer Neurological Disease
Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-101392S

Harmane-d1	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Cancer Neurological Disease
Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-151562

AChE/BuChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC₅₀s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ₁ and σ₂ receptors with K_i values of 42.8 nM (human σ₁ receptor) and 191 nM (rat σ₂ receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research.

HY-70057S1

Safinamide-d4-1 FCE 26743-d₄-1; EMD 1195686-d₄-1	Monoamine Oxidase	Neurological Disease
Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

HY-146313

BChE-IN-7	Cholinesterase (ChE)	Neurological Disease
BChE-IN-7 (compound 13) is a potent, selective, BBB-penetrated and reversible AChE and BChE inhibitor, with an IC₅₀ of 0.06 μM (BChE). BChE-IN-7 can protect neuronal-like cells from toxic Aβ-species.

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM.

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent LSD1 inhibitor. LSD1-IN-15 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM.

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent LSD1 inhibitor. LSD1-IN-16 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC₅₀ values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM.

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

1081 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1081 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L086

Neurodegenerative Disease-related Compound Library

1795 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 1795 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Type

HY-D0004

Azure B Azure B chloride	Dyes
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC₅₀s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects.

HY-14536

Methylene Blue

Basic Blue 9; CI-52015; Methylthioninium chloride

Chromogenic Assays

Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.

Cat. No.	Product Name	Type

HY-E70074

**Monoamine oxidase**	Enzyme
Monoamine oxidase is an enzyme composed of different polypeptides. Monoamine oxidation catalyzes the oxidative deamination of various biological amines in brain and peripheral tissues by producing hydrogen peroxide. Monoamine oxidase plays an important role in maintaining the regulation of synaptic transmission, emotional behavior and other brain functions.

Cat. No.	Product Name	Target	Category

HY-N9329

Glicoricone	Monoamine Oxidase Estrogen Receptor/ERR	Flavonoids Isoflavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Leguminosae Glycyrrhiza uralensis Fisch.
Glicoricone, a phenolic compound, is isolated from a species of licorice. Glicoricone is an inhibitor of monoamine oxidase (MAO), with an IC₅₀ of 140 μM. Glicoricone binds to estrogen receptor (ER) and shows estrogen antagonist activity.

HY-N9540

Methyl citrate	Monoamine Oxidase	Ketones, Aldehydes, Acids Source classification Plants Cactaceae Opuntia ficus-indica (L.) Mill.
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino.

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Monoamine Oxidase	Alkaloids Quinoline Alkaloids Classification of Application Fields Disease Research Fields Neurological Disease Source classification Plants Rutaceae
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective MAO-B (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM.

HY-W008566

Norharmane Norharman; β-Carboline	Monoamine Oxidase Endogenous Metabolite	Alkaloids Pyridine Alkaloids Indole Alkaloids Source classification Microorganisms Endogenous metabolite
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible **monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for MAO-A and MAO-B*, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana* seedlings.

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Monoamine Oxidase	Alkaloids Quinoline Alkaloids Source classification Plants Rutaceae Evodia rutaecarpa (Juss.) Benth.
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of MAO-B activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS.

HY-101392

Harmane	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Alkaloids Pyridine Alkaloids Indole Alkaloids Source classification Plants other families
Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively). Harmane exhibits comutagenic effect.

HY-22385A

Salsolidine hydrochloride	Monoamine Oxidase	Alkaloids Isoquinoline Alkaloids Source classification Plants other families
Salsolidine hydrochloride, a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive *MAO A (monoamine* oxidase A)** inhibitor.

HY-111588

Xanthoangelol	Apoptosis Monoamine Oxidase Bacterial AMPK	Chalcones Phenols Polyphenols Structural Classification Flavonoids Umbelliferae Angelica keiskei Plants Source classification Inflammation/Immunology Infection Disease Research Fields Classification of Application Fields
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-N7603

Rubrofusarin triglucoside	Monoamine Oxidase	Phenols Monophenols Ketones, Aldehydes, Acids Source classification Plants Leguminosae seeds of Cassia tora Linn. other families
Rubrofusarin triglucoside is a glycoside compound isolated from Cassia obtusifolia Linn seeds. Rubrofusarin triglucoside inhibits *human monoamine* oxidase A (hMAO-A) with an IC₅₀** of 85.5 μM.

HY-22385B

(S)-Salsolidine	Monoamine Oxidase Endogenous Metabolite	Alkaloids Isoquinoline Alkaloids Source classification Plants Chenopodiaceae Salsola
(S)-Salsolidine is a weak monoamine oxidase (MAO) inhibitor (K_i=63 μM). The R enantiomer of Salsolidine is more potent than the S form (K_i=26 μM).

HY-N6057

Obtusin	Monoamine Oxidase	Quinones Anthraquinones Phenols Polyphenols Source classification Plants Leguminosae seeds of Cassia tora Linn. other families
Obtusin, isolated from Cassia obtusifolia Linn seed, is a highly selective and competitive *human monoamine* oxidase-A (hMAO-A) inhibitor with an IC₅₀ of 11.12 μM and a K_i** of 6.15 μM. Obtusin plays a preventive role in neurodegenerative diseases, especially anxiety and depression.

HY-N8200

Cassiaside B2	Phosphatase Monoamine Oxidase 5-HT Receptor	Phenols Monophenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Caesalpiniaceae Cassia obtusifolia L.
Cassiaside B2 is a protein tyrosine phosphatase 1B (PTP1B) and *human monoamine* oxidase A (hMAO-A) inhibitor. Cassiaside B2 possesses antiallergic and is a 5-HT2C** receptor agonist...

HY-N4037

Homopterocarpin (-)-Homopterocarpin; 3,9-Dimethoxypterocarpan	Monoamine Oxidase	Structural Classification Terpenoids Other Terpenoids Pterocarpus indicus willd. Leguminosae Plants Source classification
Homopterocarpin is an isoflavonoid that can be isolated from Pterocarpus erinaceus. Homopterocarpin has hepatoprotective and antioxidant properties. Homopterocarpin is a competitive reversible inhibitor of human monoamine *oxidase-B* with an IC₅₀ and a K_i of 0.72 and 0.21 μM for hMAO-B, respectively. Homopterocarpin can be used for the research of liver injury and oxidative stress.

HY-N7204

4-Hydroxyderricin	Monoamine Oxidase Dopamine β-hydroxylase	Structural Classification Monophenols Phenols Umbelliferae Angelica keiskei Plants
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective *MAO-B (Monoamine* oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits DBH (dopamine β-hydroxylase)** activity. 4-Hydroxyderricin has antidepressant activity.

HY-N2554

Osthenol Ostenol	Monoamine Oxidase	Phenylpropanoids Coumarins Phenols Polyphenols Source classification Plants Umbelliferae Notopterygium incisum Ting ex H. T. Chang
Osthenol (Ostenol), a prenylated coumarin isolated from the dried roots of Angelica pubescens, is selective, reversible, and competitive human monoamine oxidase-A (hMAO-A) inhibitor (K_i=0.26 µM). Osthenol potently inhibits recombinant hMAO-A with an IC₅₀ of 0.74 µM and shows a high selectivity index for hMAO-A versus hMAO-B.

HY-Y0265

Isatin Indoline-2,3-dione	Monoamine Oxidase Apoptosis	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Neurological Disease Source classification Plants other families
Isatin (Indoline-2,3-dione) is a potent inhibitor of monoamine oxidase (MAO) with an IC₅₀ of 3 μM. Also binds to central benzodiazepine receptors (IC₅₀ against clonazepam, 123 μM). Also acts as an antagonist of both atrial natriuretic peptide stimulated and nitric oxide-stimulated guanylate cyclase activity. Shows effect on the serotonergic system.

Cat. No.	Product Name	Species	Source

HY-P71521

Rnls Protein, Mouse (His-SUMO)
Rnls; Renalase; EC 1.6.3.5; Monoamine Oxidase-C; MAO-C; mMAO-C
Mouse E. coli

Cat. No.	Product Name

HY-14605BS

Rasagiline-13C3 mesylate racemic
Rasagiline-¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1].

HY-Y0882S1

Hydroxylamine-d3 hydrochloride
Hydroxylamine-d₃ (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].

HY-B1111S1

Amitraz-d3
Amitraz-d₃ is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.

HY-W015490S

1,4-Naphthoquinone-d6
1,4-Naphthoquinone-d₆ is the deuterium labeled 1,4-Naphthoquinone[1]. 1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity[2].

HY-B0534S1

Moclobemide-d4
Moclobemide-d₄ is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-101392S1

Harmane-d2

Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-101392S

Harmane-d1

Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-70057S1

Safinamide-d4-1

Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

Monoamine Oxidase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products